Skip to main content

TableĀ 4 Overall survival, disease-free survival and breast cancer recurrence in the axilla in the studies comparing ALND and aRT

From: Axillary surgery in women with sentinel node-positive operable breast cancer: a systematic review with meta-analyses

Ā 

Overall survival

Disease-free survival

Breast cancer recurrence in the axilla

Ā 

AMAROS

ALND: 71/744

aRT: 76/681;

5-year: ALND: 93.3Ā % (95Ā % CI 91ā€“95);

aRT: 92.5Ā % (95Ā % CI 90ā€“94.4); HRĀ =Ā 1.17 (95Ā % CI 0.85ā€“1.62), pĀ =Ā 0.34

ALND: 124/744

aRT: 134/681;

5-year: ALND: 86.9Ā % (95Ā % CI 84.1ā€“89.3);

aRT: 82.7Ā % (95Ā % CI 79.3ā€“85.5); HRĀ =Ā 1.18 (95Ā % CI 0.93ā€“1.51), pĀ =Ā 0.18

ALND: 4/744

aRT: 7/681;

5-year:

ALND: 0.43Ā % (95Ā % CI 0ā€“0.92); aRT: 1.19Ā % (95Ā % CI 0.31ā€“2.08)

None of the studies reported local, regional, locoregional or distant breast cancer recurrence

OTOASOR

No significant difference, although no overall rates reported

ALND: 94.3Ā %

aRT: 97Ā %; non-significant

ALND: 0.82Ā %

aRT: 1.3Ā %; non-significant

  1. The relative effects of treatments on time-to-event outcomes were reported so that HRs less than 1.0 favour the aRT arm and HRs greater than 1.0 favour the ALND arm
  2. ALND axillary lymph node dissection, aRT axillary radiotherapy